M249 melanoma cells: Vemurafenib and Selumetinib resistant through BRAF double minutes vs. parental

ABSTRACT: CGH profiling of M249 melanoma cell line treated with step-wise increasing Vemurafenib and Selumetinib to develop resistance (VSR). The resistance mechanims was through BRAF amplification in double minute (DM) format. The control cell line is untreated M249.

ORGANISM(S): Homo sapiens

PROVIDER: GSE153526 | GEO | 2021/12/20

REPOSITORIES: GEO